How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014

Ilaria Marcianò,Ylenia Ingrasciotta,Francesco Giorgianni,Jenny Bolcato,Alessandro Chinellato,Roberta Pirolo,Annalisa Di Giorgio,Sonia Manna,Valentina Ientile,Rosa Gini,Mariacarmela Santarpia,Armando A. Genazzani,Ilaria Uomo,Maurizio Pastorello,Addario Sp,Salvatore Scondotto,Pasquale Cananzi,Roberto Da Cas,Giuseppe Traversa,Mariangela Rossi,Laura Sottosanti,Achille P. Caputi,Gianluca Trifirò

How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014

2016

Background Granulocyte colony-stimulating factors (G-CSFs) are biological products for which the main indication of use is chemotherapy-induced neutropenia. Biosimilars of G-CSFs have been available in Europe since 2007.

Keywords:

Neutropenia
Immunology
Biosimilar
Filgrastim
Biosimilar Pharmaceuticals
Pharmacology
Granulocyte colony-stimulating factor
Retrospective cohort study
Population
Pediatrics
Medicine
Pegfilgrastim
Granulocyte

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations